Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases

Table 3 Cox proportional hazards regression for overall survival

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age (> 65 vs ≤ 65)	0.871 (0.575-1.325)	0.423
Sex (male vs female)	0.908 (0.599-1.218)	0.278
Smoking (yes vs no)	1.071 (0.764-1.595)	0.649
ECOG (0-1 vs 2)	2.402 (0.752-7.675)	0.139
Number of brain metastases (≤ 3 vs > 3)	0.357 (0.264-0.795)	0.009	0.407 (0.299-0.857)	0.011
Tumor diameters (≤ 20 mm vs > 20 mm)	1.142 (0.752-1.675)	0.339
KRAS mutation (positive vs wild type)	0.432 (0.258-1.113)	0.405
TP53 mutation (positive vs wild type)	1.489 (1.096-2.021)	0.081
First line therapy (yes vs no)	0.612 (0.434-1.019)	0.003	0.658 (0.491-1.134)	0.025
ICI (concurrent vs consolidation)	0.385 (0.347-1.036)	0.009	0.432 (0.386-1.097)	0.007
Extracranial metastases (yes vs no)	1.601 (1.242-1.979)	0.014	1.844 (0.299-2.189)	0.036

HR: Hazard ratio; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; KRAS: Kirsten rat sarcoma viral oncogene; TP53: Tumor protein 53; ICI: Immune checkpoint inhibitor.